13 studies found for:    kalbitor
Show Display Options
Rank Status Study
1 Terminated
Has Results
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Condition: ACE Inhibitor Induced Angioedema
Interventions: Drug: ecallantide 60 mg;   Drug: ecallantide 30 mg;   Drug: ecallantide 10 mg;   Drug: placebo;   Drug: placebo match for 30 mg ecallantide arm;   Drug: placebo match for 10 mg ecallantide arm
2 Active, not recruiting Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Condition: Hereditary Angioedema
Intervention: Drug: ecallantide
3 Terminated Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement
Condition: Blood Loss, Surgical
Interventions: Drug: ecallantide;   Drug: placebo
4 Withdrawn Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema
Condition: Hereditary Angioedema
Intervention: Biological: ecallantide
5 Completed
Has Results
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Condition: Hereditary Angioedema
Intervention: Drug: ecallantide
6 Not yet recruiting Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema
Condition: Hereditary Angioedema Types I and II
Intervention: Drug: Ecallantide subcutaneous dosing
7 Completed
Has Results
Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)
Condition: Hereditary Angioedema
Interventions: Drug: ecallantide;   Drug: Phosphate Buffer Saline (PBS), pH 7.0
8 Completed
Has Results
Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)
Condition: Hereditary Angioedema (HAE)
Interventions: Drug: ecallantide;   Drug: Phosphate Buffer Saline (PBS),
9 Completed EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema
Condition: Hereditary Angioedema (HAE)
Intervention: Drug: DX-88 (ecallantide)
10 Unknown  Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Condition: Angioedema
Intervention: Drug: ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
11 Completed
Has Results
A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
Conditions: Bloodloss;   Surgical Procedures, Operative
Interventions: Drug: ecallantide;   Drug: placebo
12 Terminated Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
Conditions: Macular Edema;   Central Retinal Vein Occlusion
Intervention: Drug: FOV2302 (Ecallantide)
13 Completed
Has Results
Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery
Conditions: Bloodloss;   Surgical Procedures, Operative
Interventions: Drug: Ecallantide;   Drug: Cyklokapron(R)

Indicates status has not been verified in more than two years